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Abstract  
Background: There is an acknowledged lack of robust and rigorous research focusing on the perspectives of those prescribing direct 
acting oral anticoagulants (DOACs) for non-valvular atrial fibrillation (AF).  
Objective: The objective was to describe prescribers’ experiences of using DOACs in the management of non-valvular AF, including 
perceptions of benefits and limitations. 
Methods: A cross-sectional survey of prescribers in a remote and rural area of Scotland. Among other items, the questionnaire invited 
free-text description of positive and negative experiences of DOACs, and benefits and limitations. Responses were independently 
analysed by two researchers using a summative content analysis approach. This involved counting and comparison, via keywords and 
content, followed by interpretation and coding of the underlying context into themes.  
Results: One hundred and fifty-four responses were received, 120 (77.9%) from physicians, 18 (11.7%) from nurse prescribers and 10 
(6.4%) from pharmacist prescribers (6 unidentified professions). Not having to monitor INR was the most cited benefit, particularly for 
prescribers and patients in remote and rural settings, followed by potentially improved patient adherence. These benefits were 
reflected in respondents’ descriptions of positive experiences and patient feedback. The main limitations were the lack of reversal 
agents, cost and inability to monitor anticoagulation status. Many described their experiences of adverse effects of DOACs including 
fatal and non-fatal bleeding, and upper gastrointestinal disturbances. 
Conclusions: While prescribers have positive experiences and perceive benefits of DOACs, issues such as adverse effects and inability 
to monitor anticoagulation status merit further monitoring and investigation. These issues are particularly relevant given the trajectory 
of increased prescribing of DOACs. 
 
Keywords 
Attitude of Health Personnel; Atrial Fibrillation; Factor Xa Inhibitors; Drug Prescriptions; Health Knowledge, Attitudes, Practice; Cross-
Sectional Studies; Scotland 
 
INTRODUCTION 
Direct acting oral anticoagulants (DOACs) have superseded 
warfarin as the treatment of choice for stroke reduction in 
non-valvular atrial fibrillation (AF).1-4 Guideline 
recommendations have translated to practice, with UK 
primary care prescribing data showing a 17-fold increase in 
new DOAC users from 2012 to 2015.5 There is, however, a 
gap in the literature concerning the experiences of those 
prescribing DOACs. The one systematic review, published in 
2018, identified only ten studies, nine surveys and one 
qualitative study.6 Survey participant numbers ranged from 
38 to 450 (total of 1,246) with response rates of 9.0-35.9%, 
with outcome measures of oral anticoagulant of choice, 
factors influencing prescribing, and experiences.7-13 While 
the one qualitative study provided rich data of physicians’ 
decision-making processes regarding DOACs, the sample 
size of seven limits the likely transferability of findings.14 
One further key limitation of these studies was the 
omission of theory (e.g. cognitive, behavioural, 
organisational) in questionnaire development. There is 
acknowledgement that considering the theoretical basis is 
likely to yield a data collection tool with comprehensive 
coverage of all key factors.15,16 
Quantitative data of a recent cross-sectional survey of 
medical and non-medical prescribers (nurse and pharmacist 
independent prescribers) in a remote and rural area of 
Scotland were recently reported.17 The study was a cross-
sectional survey of medical and non-medical prescribers in 
all settings of NHS Highland, an area of low population 
density with 40% of residents living in ‘remote rural’ 
locations (defined as settlements <3000 people with a drive 
time of >30 minutes to a settlement of ≥10,000).18 Survey 
outcome measures were: prescribing of DOACs (as a 
pharmacological group); views of potential influences on 
DOAC prescribing; knowledge of prescribing guidelines; and 
experiences. Items on potential influences were based on 
the Theoretical Domains Framework (TDF, which is derived 
from 33 theories of behaviour change).19 Principal 
component analysis identified four components of 
potential influences on DOAC prescribing. Component 
scores for (a) role of professionals, their knowledge and 
skills and (b) influences on prescribing were somewhat 
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positive. Those for (c) consequences of prescribing and (d) 
monitoring for safety and effectiveness were more neutral. 
There were generally low levels of respondent agreement 
for statements about DOACs being more effective, safer 
and cost-effective than warfarin.  
Open response options were included in the questionnaire 
to provide the respondents with opportunities to describe 
in their own words their perceptions of the benefits and 
limitations of prescribing DOACs.  The aim of this paper is 
to describe these perceptions of benefits and limitations of 
using DOACs in the management of non-valvular AF. 
 
METHODS 
Study methods have been previously described, and are 
briefly outlined for completeness.17 The study was 
conducted within NHS Highland in Scotland, an area of low 
population density covering approximately 40% of the land 
mass of Scotland yet representing only 6% of the Scottish 
population.  
An online questionnaire was developed, pretested and 
piloted prior to use. Questionnaire items were in sections 
of: demographics; DOAC prescribing; potential influences 
on DOAC prescribing; knowledge of local prescribing 
guidelines; and experiences. While most question types 
were closed, 5-point Likert scales, respondents were 
invited to describe: (i) their perceptions of benefits and 
limitations of prescribing DOACs; (ii) positive patient 
experiences; and (iii) negative patient experiences, whilst 
respecting anonymity. The questionnaire was formatted in 
Snap 10 Professional® (software for web and email 
questionnaire design, publication, data entry and analysis) 
and tested for compatibility with platforms (e.g., laptop, 
tablet and smartphone), browsers, and NHS email and 
internet filters. Data collection took place from April to July 
2017. An email from a senior member of the research team 
based within NHS Highland was sent all prescribers 
(medical and non-medical), with a link to the participant 
information leaflet and the questionnaire. The 
questionnaire was to be completed only by those 
prescribing oral anticoagulants at the time of the study or 
likely to do so in the near future. Two email reminders 
were sent to all prescribers at 4-weekly intervals. Free text 
comments relating to benefits, limitation and experiences 
were analysed using a summative content analysis 
approach.20 This involved counting and comparison, via 
keywords and content, followed by interpretation and 
coding of the underlying context into themes. Analysis was 
undertaken independently by two researchers (DG, DS) and 
a third (SC) consulted when non-consensus arose.  
This study was approved by the Ethics Committee of the 
School of Pharmacy and Life Sciences at Robert Gordon 
University, UK; the study was deemed exempt from NHS 
ethical review by the North of Scotland Research Ethics 
Committee. Management approval was obtained from NHS 
Highland Research and Development Committee (ID1158). 
 
RESULTS  
One hundred and fifty-four responses were received, 120 
(77.9%) from physicians (76 general practitioners), 18 
(11.7%) from nurse prescribers and 10 (6.4%) from 
pharmacist prescribers (6 unidentified professions). As the 
questionnaire was to be completed by those for whom 
DOAC prescribing was relevant to their practice, a response 
rate could not be calculated. Respondent mean age was 
43.3 years (standard deviation 11.9 years); just over half 
(n=84, 54.5%) had >20 years’ experience as health 
professionals and slightly less (n=61, 39.6%) as prescribers; 
two thirds (n=100, 64.9%) were based in primary care. 
Counts of the number of respondents and illustrative 
quotes are given for the major themes identified in the 
summative content analysis.    
Ninety-nine respondents (71.7%) provided responses 
around perceived benefits and limitations. 
Perceived benefits  
The overwhelming benefit, cited by 47 respondents, was 
the absence of need for INR monitoring, 
“We have been overwhelmed with the need to do 
regular blood monitoring of patients in recent 
years…No additional resources have been made 
available in spite of a 300% increase in blood 
tests…anything which reduces this, such as the use 
of DOACs instead of warfarin, helps us to survive.” 
The absence of need for monitoring was often mentioned 
in the context of other benefits such as particular patient 
groups, 
“No need for monitoring, especially practical in 
elderly/housebound.” 
This was also relevant to those in remote settings, 
“It is much easier for patients who live in rural areas to be 
prescribed a DOAC especially in the winter where it is 
difficult to travel to have INR checked.” 
Cost was also a consideration, 
“No need to monitor therefore cost-effective” 
Thirteen respondents commented on the likelihood of 
better adherence, 
”Patients understand why they take these drugs 
and often state how it is much easier to take than 
warfarin especially with the interactions of diet.” 
Eleven noted benefits in terms of the evidence base, 
“Overall the evidence is that DOACs are at least as 
good as warfarin for preventing stoke and have a 
lower incidence of fatal bleeding”. 
Ten commented on the more favourable dosing regimens 
compared to warfarin, 
“…and a single daily dose, not changing like 
warfarin.” 
Ten respondents remarked on the benefits in those with 
labile INRs, 
“less likely to get out of therapeutic range…suitable 
for patients with fluctuating INR.” 
Less commonly cited benefits were better use of general 
practitioner (GP) time, especially in remote areas, reduced 
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frequency of adverse drug reactions (ADRs), and easier 
patient management.  
Perceived limitations 
The key limitation, cited by 31 respondents, was the lack of 
a suitable reversal agent, 
“Significant concerns regarding how to reverse 
anticoagulation in patients who then sustain injury/ 
head trauma.” 
“No antidote yet for rivaroxaban or apixaban.” 
The high acquisition costs of DOACs compared to warfarin 
was considered a limitation by 17 respondents, 
“I'd prescribe it more for patients with AF if health 
board not breathing down my neck about cost.” 
One respondent commented that whilst the drug costs 
were higher, there were savings when considering other 
associated costs,  
“Costly but saves on nurse/lab/doctor time to dose 
warfarin.”  
Ten respondents were concerned by the lack of ability to 
monitor anticoagulation status,  
“the main negative is the lack of longer term follow 
up to ensure patients CONTINUE to take the drug 
as prescribed regularly and on time.” 
This was a particular concern in specialist areas of practice, 
“When injecting a joint I prefer to know a patient is 
on warfarin as I can just check their INR. If they are 
on DOAC, they have to stop their medication the 
previous day, I then have to book them in early in 
the morning and then they take their next dose 
mid-day.” 
Eight noted concerns over the lack of long-term evidence of 
benefit, 
“Concerned that long term benefits may not be as 
great as expected, i.e.  problems of this group of 
drugs will show after they have been used for more 
years” 
Less commonly cited limitations were around increased 
prevalence of adverse effects and dose adjustment in renal 
impairment.  
Positive patient experiences 
Seventy-two respondents (52.2%) described positive 
experiences of DOACs. As with benefits, the main positive 
experiences surrounded the absence of need to monitor 
INR, cited by 38 respondents, 
“90 year old on warfarin for AF for 20 years. 
Became unable to drive and a lot of strain on family 
for weekly INR with no capacity in single handed 
GP to visit frequently.” 
Several described similar experiences, which were 
considered particularly relevant to those living in remote 
areas, 
“Initiating anticoagulation in patient who lives 
miles away, avoiding blood tests, living over 30 
miles from GP surgery”. 
Nineteen respondents described positive feedback from 
patients, 
“Feedback from patients has been positive - they 
no longer have to frequently attend the surgery, 
they can go on holiday more easily, they can be 
more relaxed with the choice of diet.” 
In some situations, patients had declined warfarin but were 
willing to commence DOACs, 
“Another patient would not accept warfarin but did 
DOAC”. 
Seven respondents commented on enhanced management 
of those with previously labile INRs, 
“A patient whose INR was impossible to keep in 
therapeutic range was able to get proper 
treatment”. 
Less commonly cited experiences were around better 
patient management and more rapid, effective 
anticoagulation. 
Negative patient experiences 
Descriptions of negative patient experiences were provided 
by 64 respondents (46.4%), with an additional 19 (13.8%) 
stating that they had no negative experiences to report. 
The key negative experience was around adverse events of 
bleeding, described by 24 respondents, 
“Patient admitted with severe upper GI bleed while 
on prophylactic dose after hip replacement”, 
Two respondents reported that bleeding had led to patient 
death. One noted particular concerns for those in more 
remote areas, 
“In the first month of prescribing DOACs we had 2 
major bleeds. Likely coincidence but shook 
everyone's confidence a bit, especially in a rural 
setting.” 
An additional five respondents commented on issues 
related to bleeds, 
“Emergency admission for surgery - prolonged 
operation due to increased bleeding”. 
Thirteen commented on their experiences of non-bleeding 
adverse events of varying severity and with diverse 
consequences, 
“Patient developed side effect from DOACs (severe 
nausea) and returned to warfarin”, 
“Terrible oesophagitis with dabigatran”. 
Three described issues relating to the consequences of 
rapid anticoagulation reversal on discontinuing DOACs, 
“We have had 3 patients who have had strokes 
shortly after discontinuing DOACs”. 
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Less commonly cited negative experiences included issues 
relating to inadequate monitoring of patients prior to 
commencing DOACs, 
“Colleagues not monitoring renal function and LFTs 
so overdosed DOAC and patient admitted.” 
There were also issues related to clinician lack of 
recognition of the names of DOACs as anticoagulants, 
“DOAC not stopped despite bleeding as not noted 
as a blood thinner in same way as warfarin.” 
Patient anxiety was noted as a concern, 
“patients are often wary to start treatment with a 
DOAC as they are aware of the lack of antidote.” 
Table 1 provides a summary of the key themes identified. 
 
DISCUSSION 
Content analysis of the textual comments captured in this 
survey complement the quantitative data recently 
published.17 Not having to monitor INR was the most cited 
benefit, particularly for prescribers and patients in remote 
and rural settings, followed by potentially improved patient 
adherence. These benefits were reflected in descriptions of 
positive experiences and patient feedback. The main 
limitations were the lack of reversal agents, cost and 
inability to monitor anticoagulation status. Many described 
experiences of adverse effects including fatal and non-fatal 
bleeding, and upper GI disturbances.  
This study adds to the limited evidence base of prescribers’ 
experiences of DOACs, and is timely given that DOACs are 
now recommended first line for those with non-valvular 
AF.1-6 However, given that data were collected in one 
remote and rural area of Scotland, the results may lack 
generalisability and transferability to other settings. 
Furthermore, the data were collected using a cross-
sectional survey methodology rather than through a 
qualitative approach (e.g. interviews and focus groups) 
which limited the depth of enquiry. As the findings 
represent perceptions of benefits and limitations, the 
analysis was not informed by any theoretical framework.  
Studies of healthcare provision in remote and rural areas 
have identified access as an issue, particularly in older 
populations and those with higher healthcare utility.21-26 
While many positive perceptions of DOACs identified in this 
study may be generic to all settings, these are particularly 
relevant in such areas. The specific site of action of DOACs 
on the coagulation cascade, predictable pharmacokinetic 
and pharmacodynamic properties and fixed dosages 
eliminate the need and usefulness of INR monitoring.27 Not 
having to monitor was perceived as a major benefit, and 
was highlighted in descriptions of patient positive 
experiences. However, lack of monitoring was also 
perceived a limitation, specifically the lack of ability to 
closely monitor coagulation status. These are original 
findings, not having been reported in the systematic review 
of clinicians’ experiences, nor any systematic reviews of 
patients’ experiences.6,28,29  
Adverse reactions, most notably bleeding related, were 
described by many respondents. It is, however, worth 
noting that evidence so far indicates that DOACs are 
associated with clinically important reductions in the 
frequency of major bleeding, including life-threatening 
bleeding events and, especially, intracranial bleeding, when 
compared with patients receiving warfarin.2-4 In the UK, 
DOACs are labelled ‘black triangle drugs’ meriting reporting 
of all adverse reactions (irrespective of severity) to the 
Medicines and Healthcare products Regulatory Agency.30 
Given that under-reporting is a major limitation of 
pharmacovigilance processes, further research on DOAC 
reporting is warranted. There were also descriptions of 
adverse events attributed to rapid reversal of 
anticoagulation following DOAC discontinuation prior to 
surgical intervention, as noted by others.31,32 Guidelines on 
the management of patients prescribed DOACs requiring 
elective and emergency procedures are emerging.27 
Concerns of managing DOAC related bleeding may also 
diminish with the licensing of idarucizumab to reverse 
dabigatran in patients with life threatening haemorrhage or 
need for urgent surgery.33 Andexanet alfa, a class-specific 
antidote for the factor Xa inhibitors, is now available and 
other DOAC reversal agents are in development.34 
Different views were given in relation to DOAC cost, with 
some describing cost as a limitation while others believed 
Table 1. Summary of key themes identified 
Perceived benefits Perceived limitations Positive patient experiences Negative patient experiences 
Absence of the need for INR 
monitoring (n=47) 
Lack of suitable reversal agents 
(n=31) 
Absence of the need for INR 
monitoring (n=38) 
ADRs, bleeding (n=24) 
Better patient adherence 
(n=13) 
High acquisition costs (n=17) Positive patient feedback (n=19) ADRs, non-bleeding (n=13) 
Positive evidence base (n=11) Lack of ability to monitor 
anticoagulation status (n=10) 
Enhanced management in those 
with labile INRs (n=7) 
Rapid anticoagulation reversal on 
discontinuation of DOACs (n=3) 
More favourable dosing 
regimen compared to 
warfarin (n=10) 
Lack of long-term evidence (n=8) Less commonly cited – better 
patient management, more rapid 
and effective anticoagulation 
Less commonly cited – inadequate 
monitoring prior to commencing 
DOACs, poor clinician recognition 
of DOAC names as anticoagulants, 
patient anxiety 
Useful in those with labile 
INRs (n=10) 
Less commonly cited – increased 
prevalence of ADRs, dose 
adjustment in renal impairment 
  
Less commonly cited – better 
use of GP time, reduced 
frequency of ADRs, easier 
patient management 
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costs reduced given the additional resources incurred in 
warfarin monitoring. Systematic reviews and meta-analyses 
of the cost-effectiveness of DOACs versus warfarin have 
recommended that, while further real world data are 
required, DOACs are more cost-effective despite higher 
prescribing costs.35,36   
There was a range of views around the widespread 
adoption of DOACs with some supporting the evidence 
base of effectiveness, cost-effectiveness and safety while 
others were more cautious due to the lack of real-life, long-
term evidence. This finding has been identified for many 
newly launched agents; in a recent study of the adoption of 
cardiovascular drugs in the United States, physicians were 
found to be generally conservative, with a minority 
adopting dabigatran, aliskiren or pitavastatin in the first 15 
months of market launch market.37 
Given the findings of this study and the change in Scottish 
national recommendations, there is a need for quantitative 
and qualitative data on views and experiences of 
prescribers and patients. Focus should be placed on 
identifying, characterising and reporting adverse drug 
reactions. 
 
CONCLUSIONS 
Prescribers in the Scottish Highlands highlighted positive 
and negative perceptions of DOACs in the management of 
non-valvular AF. While absence of INR monitoring was 
considered a key benefit, there were concerns around 
adverse effects, most notably bleeding. These issues merit 
further monitoring and investigation, particularly relevant 
given the trajectory of increased prescribing of DOACs. 
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